Income Taxes (Tables)

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign

Income (loss) before income taxes from U.S. and foreign operations were as follows:

	Year Ended December 31,
	2024		2023		2022
U.S.	$	75,651	$	174	$	(16,866)
Foreign	22,048		26,602		(7,019)
Total income (loss) before income taxes	$	97,699	$	26,776	$	(23,885)

Schedule of Components of Income Tax Expense (Benefit)

Total income tax expense included in the Consolidated Statements of Operations is comprised of the following:

	Year Ended December 31,
	2024		2023		2022
Current:
Federal	$	5,437	$	829	$	—
State	1,786		(99)		242
Foreign	3,443		6,835		5,482
Total current	$	10,666	$	7,565	$	5,724
Deferred:
Federal	$	144	$	140	$	368
State	1		(120)		44
Foreign	2,396		(218)		(2,217)
Total deferred	2,541		(198)		(1,805)
Income tax expense	$	13,207	$	7,367	$	3,919

Schedule of Effective Income Tax Rate Reconciliation

The following table reconciles our benefit of income taxes at the statutory rate to the effective tax rate, using a U.S. federal statutory tax rate of 21%:

	Year Ended December 31,
	2024		2023		2022
Income tax expense (benefit) at federal statutory rate	$	20,517	$	5,623	$	(5,016)
State and local taxes, net of federal benefit	1,412		(2,509)		(205)
Foreign tax rate differential	(3,858)		1,030		168
Stock-based compensation deductions	(5,698)		(17,998)		(3,077)
Nondeductible expenses	2,206		(14)		3,603
Unrecognized tax positions	4,360		1,083		1,482
Net change in valuation allowance	44,559		138		4,442
Global intangible low-tax income	110		—		1,091
Foreign-derived intangible income deduction	(3,140)		(970)		(664)
162(m) limitation	9,295		17,072		7,058
U.S. R&D tax credits	(3,402)		(2,810)		(4,432)
Valuation allowance release related to acquisition	—		(1,074)		—
Acquisition related compensation	2,659		7,811		—
Impact of intra-entity intellectual property rights transfer	(59,627)		—		—
Other	3,814		(15)		(531)
Total income tax expense	$	13,207	$	7,367	$	3,919

Schedule of Deferred Tax Assets and Liabilities

The components of deferred tax assets and liabilities are as follows:

	December 31,
	2024		2023
Deferred tax assets:
Accounts receivable	$	1,261	$	1,223
Accrued expenses	2,354		982
Capitalized research and development	44,724		30,918
Operating lease liability	32,398		44,443
Net operating loss carryforwards	11,498		28,222
Stock-based compensation	3,389		5,419
Tax credit carryforwards	17,778		18,338
Depreciation and amortization	18,538		—
Other	2,593		989
Gross deferred tax assets	134,533		130,534
Less: valuation allowance	(109,541)		(60,520)
Total net deferred tax asset	$	24,992	$	70,014
Deferred tax liability
Depreciation and amortization	$	—	$	(31,808)
Operating lease ROU asset	(28,915)		(39,745)
Total deferred tax liability	(28,915)		(71,553)
Total net deferred tax liability	$	(3,923)	$	(1,539)

Schedule of Valuation Allowance

The valuation allowance activity for the periods indicated is as follows:

	December 31,
	2024		2023
Balance as of the beginning of period	$	(60,520)	$	(47,361)
Additions charged to expense	(49,021)		(13,159)
Balance as of the end of period	$	(109,541)	$	(60,520)

Schedule of Unrecognized Tax Benefits Roll Forward

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

	Year Ended December 31,
	2024		2023		2022
Balance of unrecognized tax benefits at beginning of year	$	20,337	$	17,044	$	721
Additions based on tax positions related to the current period	5,209		1,571		3,014
Additions for tax positions of prior periods	816		1,947		2,833
Additions recorded as part of business combination	—		—		11,106
Reductions for tax positions of prior periods	(3,162)		—		(630)
Release due to expiration of statute of limitations	(808)		(225)		—
Balance of unrecognized tax benefits at end of year	$	22,392	$	20,337	$	17,044